



Heritage Pharmaceuticals – Recall of amikacin and prochlorperazine injection products

- On May 28, 2019, [Heritage Pharmaceuticals announced](#) a consumer-level recall of two lots of [amikacin](#) injection and [prochlorperazine](#) injection due to microbial growth having been detected in a couple unreleased sublots, which may indicate a lack of sterility in the other sublots.
- The recalled amikacin injection lot and prochlorperazine injection lot were distributed nationwide between June 2018 - August 2018, and October 2018 - November 2018, respectively:

Product Description	NDC#	Lot# (Expiration Date)
Amikacin sulfate injection, 1 g/4 mL (250 mg/mL)	23155-290-42	VEAC025 (10/2019)
Prochlorperazine edisylate injection, 10 mg/2 mL (5 mg/mL)	23155-294-42	VPCA172 (4/2020)

- Amikacin injection is indicated in the short-term treatment of serious infections due to susceptible strains of certain types of Gram-negative bacteria.
- Prochlorperazine injection is indicated to control severe nausea and vomiting and for the treatment of schizophrenia.
- Per Heritage, administration of non-sterile injectable products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, organ damage or death.
- To date, Heritage has not received adverse event reports related to the recalled products.
- Patients should contact their healthcare provider for further guidance and potential change of treatment before they stop taking the recalled products.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled amikacin injection or prochlorperazine injection.
- Pharmacies and healthcare facilities that have the recalled drug products should immediately quarantine and stop dispensing the recalled drug products.
- For more information regarding this recall, contact Qualanex (appointed company for Heritage) by phone at **1-800-505-9291** or by email at **recall@qualanex.com**.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.